Licensed vaccine
Fluzone Quadrivalent
FDA-licensed vaccine · Sanofi Pasteur Inc. · STN 103914
Key facts
| Trade name | Fluzone Quadrivalent |
|---|---|
| Proper name | Influenza Virus Vaccine (Quadrivalent, Types A and Types B) |
| Manufacturer | Sanofi Pasteur Inc. |
| Submission tracking number (STN) | 103914 |
| FDA product areas | Biologics, Vaccines |
| Recent FDA documents | September 26, 2024 Approval Letter - Fluzone High-Dose Quadrivalent Southern Hemisphere, July 1, 2024 Approval Letter- Fluzone and Fluzone High-Dose, February 14, 2024 Approval Letter - Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent Southern Hemisphere, November 29, 2023 Approval Letter - Fluzone, July 12, 2023 Approval Letter - Fluzone Quadrivalent and Fluzone High-Dose, Package Insert - Fluzone, February 22, 2023 Approval Letter - Fluzone High Dose Quadrivalent, February 13, 2023 Approval Letter - Fluzone Quadrivalent Southern Hemisphere and Fluzone High-Dose Quadrivalent Southern Hemisphere, Package Insert and Patient Information - Fluzone High-Dose Quadrivalent Southern Hemisphere, November 2, 2022 Approval Letter - Fluzone Quadrivalent and Fluzone Quadrivalent Southern Hemisphere, July 1, 2022 Approval Letter - Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent, February 14, 2022 Approval Letter - Fluzone Quadrivalent Southern Hemisphere |
| FDA page updated | Sep 27, 2024 |
| FDA product page | fda.gov |
At a glance
- 10–99 FDA approval letters
- 10–99 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: